Nafld Clinical Trials 2023

Nafld Clinical Trials 2023

Nafld research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in nafld clinical trials today.

Nafld Clinical Trials

Here are the 6 most popular medical studies for nafld

Montreal, Quebec

Omega-3 Fatty Acids

Omega-3 for Non-alcoholic Fatty Liver Disease

Recruiting0 awardsPhase 1 & 2
Montreal, Quebec

Nonalcoholic hepatic steatosis (NASH) is defined as the amount greater than 5% of the total liver volume fat. Commonly known as NASH, it includes 4 stages histological ranging from the mere presence of fat to the existence of fibrosis and degeneration of hepatocytes, and finally a progression to cirrhosis, sometimes accompanied by complications of hepatocellular carcinoma. It is a common condition associated with a combination of disorders, namely obesity, insulin resistance and type 2 diabetes. The link with the metabolic syndrome (MetS) was mainly studied in the adult population and very little in the paediatric population, while 15 and 25% of obese children are affectés. The severity of histological disease appears to be associated with the degree of obesity in children and particularly in the MetS. in addition, epidemiological data indicate that the incidence of this disease is increasing in children and positioning as the first NASH liver disease in North America. the revelation of the factors associated with the occurrence of NASH is a first necessary step to understanding this disorder worrying for the future of children and adolescents. In addition, clarification of the mechanisms responsible for its development is essential if the investigators want to consider targeted and effective treatments to slow the rat race of NASH, which stands out as the supreme chronic liver accompanying the obesity and MetS. Finally, in view of growth and puberty of children, it would be extremely beneficial to find nutritional avenues that would avoid the side effects of chemical agents.

Popular filter options for nafld trials

Non-alcoholic Fatty Liver Disease Clinical Trials

View 33 Non-alcoholic Fatty Liver Disease medical studies.

Metabolic Syndrome Clinical Trials

View 9 Metabolic Syndrome medical studies.

Nafld Clinical Trials With No Placebo

View 34 nafld medical studies that do not have a placebo group.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to nafld

What are the top hospitals conducting nafld research?

Amidst the rapidly growing concern over non-alcoholic fatty liver disease (NAFLD), several top hospitals have emerged as trailblazers in the field of clinical trials. In New york, Columbia University Irving Medical Center leads the way with two active NAFLD trials and a total of three completed studies dedicated to this condition. This institution made its mark by recording its first trial in 2023, demonstrating their commitment to advancing our understanding and treatment options for NAFLD. Similarly, Duke University Medical Center in Durham has been actively involved in tackling NAFLD since 2005 when they initiated their first trial. With two ongoing trials and an impressive track record of 27 previous investigations, Duke's efforts are helping shape the future management of this increasingly prevalent liver disease.

Meanwhile, at Mayo Clinic located in Rochester, Minnesota, research into NAFLD is also gaining momentum. Since commencing their initial trial in 2020, Mayo Clinic has currently undertaken two active trials while contributing to a cumulative total of three studies on this condition thus far. On the other side of Texas lies Worldwide Clinical Trials' Early Phase Services LLC based in San Antonio—a facility that may be smaller scale but nonetheless plays a crucial role within the landscape of NAFLD research. Having recorded its inaugural study on NALFD only recently in 2023 along with one current active trial underway; it proves that significant contributions can come from various institutions regardless size or location.

Lastly representing West Coast excellence is University of California, San Diego situated uniquely amidst picturesque La Jolla scenery where they have conducted eight all-time nafld clinical examinations so far while having one presently running investigation set up . Their journey began backin2009 when UCSD launched their maiden experiment focused solely on addressing Non-Alcoholic Fatty Liver Disease .

Together these leading hospitals demonstrate an unwavering dedication towards combating such ailments through innovative research approaches—each step toward unravelling secrets of NAFLD brings us closer to finding effective interventions and therapies for millions suffering worldwide.

Which are the best cities for nafld clinical trials?

When it comes to NAFLD clinical trials, several cities in the United States are at the forefront of research and innovation. San Antonio, Texas leads with 10 active trials investigating treatments like Resmetirom, Intervention/Drug, and Saroglitazar Magnesium 4 mg Tablet. Following closely behind are Chicago, Illinois and New york, New York with 5 ongoing studies each exploring interventions such as Efinopegdutide 4mg and Lisinopril. Additionally, Dallas, Texas and Tucson Arizona have 4 active trials focusing on Resmetirom, Efinopegdutide 4mg, and other potential therapies. These cities offer individuals affected by NAFLD access to cutting-edge clinical trials that may shape future treatment options for this complex condition.

Which are the top treatments for nafld being explored in clinical trials?

Clinical trials are paving the way for advancements in treating non-alcoholic fatty liver disease (NAFLD). Among the top contenders is semaglutide, currently being explored in two active trials. Since its first listing in 2016, it has become a subject of interest with a total of 11 NAFLD trials. Another promising treatment on the horizon is diazoxide oral suspension at a dosage of 1 mg per kg per dose, which is currently under investigation in one active trial and marks its debut on the clinical trial scene in 2023. These innovative approaches hold promise for improving outcomes and addressing this challenging condition.

What are the most recent clinical trials for nafld?

Important advancements are being made in the field of non-alcoholic fatty liver disease (NAFLD) through recent clinical trials. These studies aim to improve our understanding and treatment options for NAFLD, a condition characterized by excessive fat accumulation in the liver. Some of the most recent trials include evaluating the reduction toward euinsulinemia (RE) protocol, LY3885125, BI 3006337 dose group 4, diazoxide oral suspension, and bicalutamide for NAFLD patients. These trials focus on different approaches to address various aspects of the disease and have become available throughout August 2023. Through these ongoing investigations, we hope to uncover new strategies that will enhance patient outcomes and contribute to managing this prevalent health issue more effectively.

What nafld clinical trials were recently completed?

Numerous clinical trials focused on NAFLD have recently reached completion, demonstrating the commitment of researchers in addressing this prevalent liver condition. Among these trials are ALT-801 sponsored by Altimmune, Inc., which concluded in both March 2022 and September 2021; BIO89-100 sponsored by 89bio, Inc., completed in August 2021; Efinopegdutide 20 mg/mL sponsored by Merck Sharp & Dohme Corp., wrapped up in August 2021; AMG 609 sponsored by Amgen was finalized in May 2021; TERN-201 conducted under the sponsorship of Terns, Inc., achieved completion also in May 2021. Additionally, several other significant trials were successfully completed between November 2020 to December 2019 involving various pharmaceutical sponsors such as Oramed Ltd., National Institute of Allergy and Infectious Diseases (NIAID), Genentech Inc., Pfizer, NGM Biopharmaceuticals Inc., Novartis Pharmaceuticals, and Madrigal Pharmaceuticals Inc. These collective efforts underline the continuous pursuit for effective treatments for NAFLD.